-
Development of Curricular or Training Activities in Rigor and Transparency to Enhance Reproducibility (Admin Supp Clinical Trial Not Allowed)
(PA-18-756)
National Institute of General Medical Sciences
Application Receipt Date(s): May 18, 2018 by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Administrative Supplements to NIGMS Predoctoral Training Grants for the Development of Activities to Prepare Trainees for Careers in the Biomedical Research Workforce (Admin Supp Clinical Trial Not Allowed)
(PA-18-757)
National Institute of General Medical Sciences
Application Receipt Date(s): May 18, 2018 by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Development of Curricular or Training Activities in Laboratory Safety (Admin Supp Clinical Trial Not Allowed)
(PA-18-758)
National Institute of General Medical Sciences
Application Receipt Date(s): May 18, 2018 by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Development of Curricular or Training Activities in Skills Development (Admin Supp Clinical Trial Not Allowed)
(PA-18-759)
National Institute of General Medical Sciences
Application Receipt Date(s): May 18, 2018 by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
In Vivo Synaptic Function in Alzheimers Disease and Related Dementias (R21 Clinical Trial Not Allowed)
(PAR-18-760)
National Institute on Aging
Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
(PAR-18-761)
National Institute of Neurological Disorders and Stroke
Application Receipt Date(s): June 19, 2018, October 17, 2018, February 20, 2019, June 19, 2019, October 17, 2019, February 19, 2020, June 17, 2020, October 20, 2020 and February 17, 2021
apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
-
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
(PAR-18-762)
National Institute of Neurological Disorders and Stroke
Application Receipt Date(s): June 19, 2018, October 17, 2018, February 20, 2019, June 19, 2019, October 17, 2019, February 19, 2020, June 17, 2020, October 20, 2020 and February 17, 2021 apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
-
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
(PAR-18-763)
National Institute of Neurological Disorders and Stroke
Application Receipt Date(s): June 19, 2018, October 17, 2018, February 20, 2019, June 19, 2019, October 17, 2019, February 19, 2020, June 17, 2020, October 20, 2020 and February 17, 2021
apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
-
Harnessing Big Data to Halt HIV (R01 Clinical Trial Optional)
(PAR-18-764)
National Institute of Allergy and Infectious Diseases
National Cancer Institute
National Institute of Mental Health
Application Receipt Date(s): Standard AIDS dates, by 5:00 PM local time of applicant organization. All types of AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Limited Competition: Interaction of HIV Infection and Alcohol Abuse on Central Nervous System Morbidity (U01 Clinical Trial Not Allowed)
(RFA-AA-18-011)
National Institute on Alcohol Abuse and Alcoholism
Application Receipt Date(s): July 3, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
No late applications will be accepted in response to this FOA.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Targeted In Vivo Delivery of Gene Therapeutics for HIV Cure (R01 Clinical Trial Not Allowed)
(RFA-AI-18-016)
National Institute of Allergy and Infectious Diseases
National Institute of Mental Health
Application Receipt Date(s): July 31, 2018, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on thisdate.
-
Cooperative Agreement to Support the Food and Agriculture Organization (FAO) (U01)
(RFA-FD-18-009)
Food and Drug Administration
Application Receipt Date(s): July 2, 2018, by 11:59 PM Eastern Time.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date.
Late applications will not be accepted for this FOA.
-
Enhancing Innovations in Emerging Technologies for Advanced Manufacturing of Complex Biologic Products (R01)
(RFA-FD-18-023)
Food and Drug Administration
Application Receipt Date(s): June 25, 2018, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date.
Late applications will not be accepted for this FOA.
-
Novel Nucleic Acid Sequencing Technology Development (R01 Clinical Trial Not Allowed)
(RFA-HG-18-001)
National Human Genome Research Institute
Application Receipt Date(s): June 27, 2018; June 27, 2019; June 26, 2020), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Novel Nucleic Acid Sequencing Technology Development (R21 Clinical Trial Not Allowed)
(RFA-HG-18-002)
National Human Genome Research Institute
Application Receipt Date(s): June 27, 2018; June 27, 2019; June 26, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Novel Nucleic Acid Sequencing Technology Development (R43/R44 Clinical Trial Not Allowed)
(RFA-HG-18-003)
National Human Genome Research Institute
Application Receipt Date(s): June 27, 2018; June 27, 2019; June 26, 2020, by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Summer Institute for Research Education in Biostatistics (R25 - Clinical Trials Not Allowed)
(RFA-HL-19-019)
National Heart, Lung, and Blood Institute
Application Receipt Date(s): June 28, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R01 Clinical Trial Not Allowed)
(RFA-NS-18-030)
National Institute of Neurological Disorders and Stroke
National Institute on Alcohol Abuse and Alcoholism
National Institute on Aging
National Institute on Drug Abuse
National Institute on Deafness and Other Communication Disorders
National Eye Institute
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute of Mental Health
National Center for Complementary and Integrative Health
National Institute of Biomedical Imaging and Bioengineering
Office of Research on Women's Health
Office of Behavioral and Social Sciences Research
Application Receipt Date(s): July 3, 2018; N?o?v?e?m?b?e?r? ?6, 2018; July 3, 2019; November 6, 2019; July 1, 2020; November 10, 2020by 5:00 PM local time of applicant organization.All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.